SCHEMBL474810

SCHEMBL474810

CCOCCN1CCOCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
MAPK1 P28482 2/20 0.51
CYP1A2 P05177 1/20 0.51
CHRM2 P08172 1/20 0.51
CHRM1 P11229 1/20 0.51
HTR2A P28223 1/20 0.51
SCN1A P35498 1/20 0.51
HTR2B P41595 1/20 0.51
KCNH2 Q12809 1/20 0.51
SCN2A Q99250 1/20 0.51
SIGMAR1 Q99720 1/20 0.51
SCN3A Q9NY46 1/20 0.51
HRH3 Q9Y5N1 1/20 0.51
KDM4E B2RXH2 3/20 0.50
USP2 O75604 1/20 0.50
LMNA P02545 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.48
KEAP1 Q14145 1/20 0.48
HTT P42858 2/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL2354924 0.98 ALDH1A1 (0.50) ALDH1A1MAPK1CYP1A2CHRM2CHRM1
SCHEMBL14524633 0.98 ALDH1A1 (0.50) ALDH1A1MAPK1CYP1A2CHRM2CHRM1
SCHEMBL3299959 0.96 KDM4E (0.55) ALDH1A1MAPK1CYP1A2CHRM2CHRM1
SCHEMBL19801508 0.92 ALDH1A1 (0.46) ALDH1A1MAPK1CYP1A2CHRM2CHRM1
SCHEMBL22416459 0.92 ALDH1A1 (0.46) ALDH1A1MAPK1CYP1A2CHRM2CHRM1
SCHEMBL2614641 0.92 HRH3 (0.57) ALDH1A1MAPK1CYP1A2CHRM2CHRM1
SCHEMBL10922490 0.90 ALDH1A1 (0.55) ALDH1A1MAPK1CYP1A2CHRM2CHRM1
SCHEMBL19801513 0.89 KDM4E (0.50) ALDH1A1MAPK1CYP1A2CHRM2CHRM1
SCHEMBL19801507 0.89 KDM4E (0.50) ALDH1A1MAPK1CYP1A2CHRM2CHRM1
SCHEMBL21348421 0.88 MAPK1 (0.54) ALDH1A1MAPK1CYP1A2CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411435-A1 POLYURETHANE GELS AND METHOD FOR THE PRODUCTION THEREOF GT Elektrotechnische Produkte GmbH (DE) 2012-02-01 EP claimed
WO-2010108541-A1 POLYURETHANE GELS AND METHOD FOR THE PRODUCTION THEREOF GT ELEKTROTECHNISCHE PRODUKTE GMBH (DE) 2010-09-30 WO claimed
EP-1525235-A1 MICROSTRUCTURE CHAIN TRANSFER AGENTS FOR ANIONIC POLYMERIZATION Hellermann, Walter (DE) 2005-04-27 EP claimed
WO-2004014966-A1 MICROSTRUCTURE CHAIN TRANSFER AGENTS FOR ANIONIC POLYMERIZATION HELLERMANN WALTER (DE) 2004-02-19 WO claimed
EP-4281439-A1 SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES The Scripps Research Institute (US) 2023-11-29 EP disclosed
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2023-11-09 US disclosed
EP-4272825-A2 MTORC MODULATORS AND USES THEREOF Aeovian Pharmaceuticals, Inc. (US) 2023-11-08 EP disclosed
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
WO-2023109912-A1 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF BEIGENE, LTD. (KY) 2023-06-22 WO disclosed
US-20230142839-A1 N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases ARRAY BIOPHARMA INC. (US) 2023-05-11 US disclosed
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2022-12-13 US disclosed
US-20220389017-A1 NOVEL PURINE DERIVATIVE, INTERMEDIATE AND APPLICATION THEREOF IN PREPARING ANTICANCER MEDICINE SUZHOU RAYMON PHARMACEUTICALS COMPANY, LTD. (CN) 2022-12-08 US disclosed
US-4077859-A Polyunsaturated halogenated monomers for use in ultraviolet coating systems CELANESE CORPORATION (US) 1978-03-07 US disclosed
US-4042476-A TITANIUM DIOXIDE-ACRYLIC POLYMER EMULSION CELANESE CORPORATION (US) 1977-08-16 US disclosed
US-4035321-A Preparation of ultraviolet curable acrylated polymers CELANESE CORPORATION (US) 1977-07-12 US disclosed
US-4016334-A Method of applying high adhesion ultraviolet curable coatings and coated articles CELANESE CORPORATION (US) 1977-04-05 US disclosed
US-4008293-A ACRYLIC COPOLYMER, AMINOPLAST, BINDER PPG INDUSTRIES, INC. (US) 1977-02-15 US disclosed
US-3992276-A Unsaturated polyesters for ultraviolet curable coatings CELANESE CORPORATION (US) 1976-11-16 US disclosed
US-3992275-A Low gloss ultraviolet curable coatings utilizing α,α,α-trichlorotoluene as a photoinitiator CELANESE CORPORATION (US) 1976-11-16 US disclosed
US-3943153-A BACTERICIDES MERCK & CO., INC. (US) 1976-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220389017-A1 NOVEL PURINE DERIVATIVE, INTERMEDIATE AND APPLICATION THEREOF IN PREPARING ANTICANCER MEDICINE PNP, ENTPD5, NTPCR ALDH1A1 999/4885MAPK1 152/4885CYP1A2 2642/4885
US-20230142839-A1 N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases ERBB4, ERBB2, ERBB3 ALDH1A1 2816/4885MAPK1 182/4885CYP1A2 2406/4885
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF KRAS, NRAS, HRAS ALDH1A1 1158/4885MAPK1 435/4885CYP1A2 1409/4885
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL ALDH1A1 2252/4885MAPK1 4455/4885CYP1A2 2410/4885
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV ALDH1A1 1863/4885MAPK1 4249/4885CYP1A2 746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.